Structure Therapeutics (GPCR) EBITDA (2022 - 2026)

Structure Therapeutics' EBITDA history runs 5 years deep, the most recent figure standing at -$79.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 68.79% year-over-year to -$79.2 million; the TTM figure through Mar 2026 stood at -$173.3 million (down 21.72% YoY), while the FY2025 annual figure was -$141.1 million, down 15.5% from the prior year.
• EBITDA was -$79.2 million for Q1 2026 at Structure Therapeutics, down from $33.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $33.2 million in Q4 2025 to a low of -$79.2 million in Q1 2026.
• Historically, EBITDA has averaged -$28.4 million across 5 years, with a median of -$23.8 million in 2023.
• Biggest YoY gain for EBITDA was 186.54% in 2025; the steepest drop was 135.0% in 2025.
• A 5-year view of EBITDA shows it stood at -$11.8 million in 2022, then plunged by 99.76% to -$23.7 million in 2023, then slumped by 62.23% to -$38.4 million in 2024, then soared by 186.54% to $33.2 million in 2025, then tumbled by 338.37% to -$79.2 million in 2026.
• The last three EBITDA figures came in at -$79.2 million (Q1 2026), $33.2 million (Q4 2025), and -$65.2 million (Q3 2025), per Business Quant data.